Answers are grounded in this paper and cite their sources.
KRAS, one of the most common oncogenic mutations, is considered to be a potential target for design of cancer therapies. Previous studies have suggested a poor therapeutic index and lack of efficacy of drugs targeting the KRAS signalling pathway and even leading to think “undrugged”. But recently, major breakthrough in KRAS was achieved in a decade and even up to hit the market which really inspired a lot. This review aims to illustrate the recent advances of drug design strategies for different types of KRAS mutations, including small molecular inhibitors, PROTAC and others.
No takes yet. Share an insight, caveat, or question.
Xulin Huang (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: